IDEXX Q1 beats: rev $1.14B (+14%), EPS $3.47 (+17%); raises FY guidance

IDEXX LABORATORIES INC /DE

2026-Q1 EPS reported $3.47 revenue$1,140,820,000

Q1 revenue $1,141M (+14% as reported, +11% organic); EPS $3.47 (+17% as reported, +15% comparable).
CAG Diagnostics recurring revenue +14% as reported, +11% organic; premium instrument installed base +12%.
FY2026 revenue guidance raised $42M at midpoint to $4,675-$4,760M; EPS guidance to $14.45-$14.90.
Organic revenue growth guidance raised to 7.7%-9.7% from 7.0%-9.0%; operating margin expansion 50-90 bps.
CEO Jay Mazelsky to transition; Mike Erickson will continue as a key leader (mentioned in earnings release).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IDEXX LABORATORIES INC /DE reported the quarter ended March 31, 2026 results: revenue $1,141 million, EPS $3.47. Guidance raised.

Period: the quarter ended March 31, 2026
Revenue: $1,141 million
EPS: $3.47
Guidance: raised
Result: reported results

Exact text from the filing

Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $1,141 million for the first quarter of 2026, an increase of 14% as reported and 11% organic, driven by Companion Animal Group ("CAG") growth of 15% as reported and 12% organic. First quarter

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

IDEXX LABORATORIES INC /DE filing history →

Source: SEC EDGAR

accession 0001104659-26-055203

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.